


Form PTO-1449



Docket No. 131561200100

Appl. No. 09/434,345

INFORMATION DISCLOSURE
STATEMENT

Applicant(s)

Teni BOULIKAS

Filing Date: November 5, 1999

Group Art Unit: 1615

(use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
<i>B</i>	1.	02/28/95	5,393,530	Schneider et al.			
<i>J</i>	2.	04/13/99	5,894,060	Boulikas			
<i>C</i>	3.	08/31/99	5,945,122	Abra et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
<i>B</i>	4.	Boulikas, T., "Evolutionary consequences of nonrandom damage and repair of chromatin domains" <i>J. Mol. Evol.</i> 35:156-180 (1992).
	5.	Boulikas, T., "DNA lesion-recognizing proteins and the p53 connection" <i>Anticancer Res.</i> 16:225-242 (1996).
	6.	Boulikas, T., "Status of gene therapy in 1997: Molecular mechanisms, disease targets, and clinical applications" <i>Gene Ther. Mol. Biol.</i> 1:1-172 (1998).
	7.	Boulikas, T., "Nucleocytoplasmic trafficking: implications for the nuclear import of plasmid DNA during gene therapy" <i>Gene Ther. Mol. Biol.</i> 1:713-740 (1998).
	8.	Decout, A. et al., "Contribution of the hydrophobicity gradient to the secondary structure and activity of fusogenic peptides" <i>Mol. Membr. Biol.</i> 16(3):237-246 (1999).
	9.	Duguid, J.G. et al., "A physicochemical approach for predicting the effectiveness of peptide-based gene delivery systems for use in plasmid-based gene therapy" <i>Biophys. J.</i> 74:2802-2814 (1998).
	10.	Farhood, H. et al., "Cationic liposomes for direct gene transfer in therapy of cancer and other diseases" <i>Ann. N.Y. Acad. Sci.</i> 716:23-35 (1994).
	11.	Kim, J.C. et al., "Synthesis and antitumor evaluation of <i>cis</i> -(1,2-diaminoethane) dichloroplatinum (II) complexes linked to 5- and 6-methylneuracil and -uridine analogues" <i>Arch. Pharm. Res.</i> 21(4):465-469 (1998).
	12.	Martin, F. and Boulikas, T., "The challenge of liposomes in gene therapy" <i>Gene Ther. Mol. Biol.</i> 1:173-214 (1998).
<i>J</i>	13.	Martin, I. and Ruysschaert, J-M., "Comparison of lipid vesicle fusion induced by the putative fusion peptide of fertilin (a protein active in sperm-egg fusion) and the NH2-terminal domain of the HIV2 gp41" <i>FEBS Lett.</i> 405(3):351-355 (1997).


EXAMINER:

DATE CONSIDERED:

8/6/01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449



Docket No. 131561200100

Appl. No. 09/434,345

INFORMATION DISCLOSURE
STATEMENT

Applicant(s)

Teni BOULIKAS

Filing Date: November 5, 1999

Group Art Unit: 1615

(use several sheets if necessary)


14.	Martin, I. et al., "Membrane fusion induced by a short fusogenic peptide is assessed by its insertion and orientation into target bilayers" <i>Biochemistry</i> 38(29):9337-9347 (1999).
15.	Morikawa, K. et al., "Synthesis of platinum complexes of 2-aminomethylpyrrolidine derivatives for use as carrier ligands and their antitumor activities" <i>Chem. Pharm. Bull. (Tokyo)</i> 38(4):930-935 (1990).
16.	Papadopoulou, M.V. et al., "NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide <i>in vivo</i> " <i>Int. J. Radiation Oncol. Biol. Phys.</i> 42(4):775-779 (1998).
17.	Pécheur, E.I. et al., "Membrane anchorage brings about fusogenic properties in a short synthetic peptide" <i>Biochemistry</i> 36(13):3773-3781 (1997).
18.	Stathopoulos, G.P. et al., "Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin" <i>Oncol. Rep.</i> 6(4):797-800 (1999).
19.	Zhang, M. et al. "Studies on Cisplatinum Albumin Microspheres for Lung Targeting" <i>Acta Pharmaceutica Sinica</i> 29 (5):380-386 English Abstract on p. 386 (1994).

8/6/01

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



A# 3

Form PTO-1449	Docket No. 131561200100	Appl. No. 09/434,345
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Teni Boulikas	
	Filing Date: November 5, 1999	Group Art Unit: 1615
(use several sheets if necessary)		

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.						
	2.						
	3.						

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
	4.						
	5.						
	6.						

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
Or	7.	Boulikas, T., "The Nonuniform Repair of Active and Inactive Chromatin Domains" <i>Int. J. Onco.</i> 8:65-75 (1996).
	8.	Boulikas, T., "A Unified Model Explaining the Preferential Repair of Active Over Inactive Genes and of the Transcribed Over the Nontranscribed Strand: A Leading Role for Transcription Factors and Matrix Anchorage" <i>Int. J. Oncol.</i> 8:77-84 (1996).
	9.	Boulikas, T., "Status of Gene Therapy in 1997: Molecular Mechanisms, Disease Targets, and Clinical Applications" <i>Gene Ther. Mol. Biol.</i> 1:1-172 (1998).
	10.	Boulikas, T., "Nucleocytoplasmic Trafficking: Implications for the Nuclear Import of Plasmid DNA During Gene Therapy" <i>Gen. Ther. Mol. Biol.</i> 1:713-740 (1988).
	11.	Martin, F. et al., "The Challenge of Liposomes in Gene Therapy" <i>Gene Ther. Mol. Biol.</i> 1:173-214 (1988).
	12.	
	13.	
	14.	
	15.	
	16.	
	17.	
	18.	
	19.	
	20.	
	21.	
	22.	

EXAMINER:

DATE CONSIDERED:

8/6/01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

4,345



1638

Patent & Trademark Office

1971

JUN 26 2001

JOINT INTERNATIONAL PATENT EXAMINERS

STATEMENT			
(use several sheets if necessary)			
			
Exam. Initials	Ref. No.	Date	Document No.
1	1	10/10/96	1003 124

RECEIVED
JUL 03 2001

TECH CENTER 1600/2900

ECH CENTER 1600/2900

(including author, title, date, pertinent pages, etc.)

(including author, title, date, pertinent pages, etc.)

[Signature]